Jennifer Ruddock | Senior Vice President, Strategy and Corporate Affairs |
Howard Robin | President, Chief Executive Officer |
Jonathan Zalevsky | Chief Research & Development Officer |
Brian Kotzin | Interim Chief Medical Officer, Head of Development |
Gil Labrucherie | Chief Operating Officer, Chief Financial Officer |
Peter Lawson | Barclays |
Jay Olson | Oppenheimer |
Jessica Fye | JPMorgan |
Paul Choi | Goldman Sachs |
Difei Yang | Mizuho Securities |
Andy Hsieh | William Blair |
Ben Burnett | Stifel |
Ladies and gentlemen, thank you for standing by and welcome to the Nektar Therapeutics fourth quarter 2020 financial results. At this time, all participants' lines are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference may be recorded.